ArticlePain and therapy2026
Results from TRIUMPH [EUROPE], a Real-World Observational Study on the 3-Month Effectiveness of Galcanezumab Versus Traditional Oral Migraine Preventive Medications.
Article in Pain and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Calcitonin Gene-Related Peptide (CGRP): Biology, Signaling, Pathophysiological Roles, and Therapeutic Applications.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGalcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide, has shown efficacy in migraine prevention in clinical trials and has been included in clinical guidelines. Nonetheless, data on its real-world effectiveness are limited.
methodsTRIUMPH [Europe], an ongoing prospective study, enrolled patients ≥ 18 years old with migraine from Germany, Italy, Spain, and the UK who were initiating or switching to galcanezumab or traditional oral migraine preventive medications (TOMPs) between June 2020 and February 2023. The primary end point at 3 months was the percentage of patients achieving a response in monthly headache days (MHDs) as defined by a percentage reduction of ≥ 50% for episodic migraine and ≥ 30% for chronic migraine. The TRIUMPH [Europe] results are descriptive, as no alpha was allocated for comparative formal hypothesis testing between treatment groups.
resultsA total of 717 patients were enrolled, with 46.0% in the galcanezumab and 40.9% in the TOMP groups. In the galcanezumab and TOMP groups, 85.8% and 85.3% of patients were women, respectively, and had a mean age of 44.4 and 36.8 years. Chronic migraine was more represented in the galcanezumab group than in the TOMP group (60.9% versus 32.4%). At baseline, mean (standard deviation [SD]) MHDs were 14.8 (7.2) for galcanezumab and 10.3 (5.2) days for TOMP. At 3 months, mean (SD) MHDs were 7.7 (7.4) and 6.8 (5.5) days for galcanezumab and TOMP, respectively. The 3-month weighted proportion of responders for galcanezumab and TOMP, respectively, was 63.1% and 34.9% overall, 60.7% and 29.9% for episodic migraines, and 65.0% and 42.6% for chronic migraines. Changes from baseline in the mean number of MHDs with acute medication use were -6.6 for galcanezumab and -2.9 for TOMP.
conclusionsAfter 3 months of migraine preventive treatment, the proportion of responders trended numerically higher among patients with migraine initiating/switching to galcanezumab than among those receiving TOMP.
trial registrationThis study was registered through the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (number EUPAS33068).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.